NIKI (Niki BioSolutions) Tariff Resilience Score: 3/10 (As of Jul. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NIKI Niki BioSolutions Inc NIKI
56 GF Score
Price $9.54
GF Value $11.69
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Niki BioSolutions Tariff Resilience Score?

Niki BioSolutions NIKI +11.06% 56 Tariff Resilience Score is 3 as of Jul. 22, 2026. GuruFocus rates NIKI with a GF Score™ of 56/100 and a GF Value™ of $11.69 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 1,370 Biotechnology companies, Niki BioSolutions ranks worse than 50.44% on this metric.

Niki BioSolutions has the Tariff Resilience Score of 3, which implies that the company might have .

Niki BioSolutions has Aptorum Group Ltd is highly vulnerable to tariffs due to its dependence on international supply chains for pharmaceutical ingredients. The company has limited mitigation strategies and pricing power, increasing its exposure to tariff impacts.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Niki BioSolutions might have .

Niki BioSolutions  (NAS:NIKI) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Niki BioSolutions Tariff Resilience Score Related Terms

NIKI vs LABT, NCNA, SNGX: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Niki BioSolutions's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Niki BioSolutions Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Niki BioSolutions's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Niki BioSolutions's Tariff Resilience Score falls into.


NIKI
56GF Score
Niki BioSolutions Inc NIKI
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 3 mean?
Niki BioSolutions (NIKI) has a Tariff Resilience Score of 3 as of Jul. 22, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Niki BioSolutions ranks #691 out of 1370 companies in the Biotechnology industry, placing it in the top 50.4%.
Is Niki BioSolutions' Tariff Resilience Score too high?
Niki BioSolutions' current Tariff Resilience Score is 3. The Biotechnology industry median Tariff Resilience Score is 4.00. Niki BioSolutions' value of 3 is 25% below this industry median. Based on the distribution chart, Niki BioSolutions ranks #691 out of 1370 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Niki BioSolutions has a GF Score™ of 56/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Niki BioSolutions' Tariff Resilience Score compare to LABT and NCNA?
According to the Biotechnology industry distribution chart, Niki BioSolutions ranks #691 out of 1370 companies for Tariff Resilience Score. This places Niki BioSolutions in the lower half of its industry. The industry median Tariff Resilience Score is 4.00. Niki BioSolutions' value of 3 is 25% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,370 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Niki BioSolutions's current Tariff Resilience Score of 3 is 25% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Niki BioSolutions's current Tariff Resilience Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Niki BioSolutions stock overvalued right now?
Based on GuruFocus' analysis, Niki BioSolutions (NIKI) is currently considered Modestly Undervalued. The stock's GF Value™ is $11.69, compared to a current price of $9.54 — trading 18.4% below its estimated fair value. The current Tariff Resilience Score is 3 and 25% below the Biotechnology industry median of 4.00. Niki BioSolutions' overall GF Score™ is 56/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Niki BioSolutions (NIKI), the current Tariff Resilience Score is 3 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Niki BioSolutions (NIKI) Overvalued in 2026?

Based on GuruFocus' analysis, Niki BioSolutions stock appears to be undervalued. The current stock price of $9.54 is trading 18.4% below its estimated GF Value™ of $11.69. GuruFocus considers Niki BioSolutions to be Modestly Undervalued.

Key valuation signals for NIKI:

  • Tariff Resilience Score: 3
  • GF Value™: $11.69 vs. price of $9.54 (18.4% below fair value)
  • GF Score™: 56/100 with 1 warning sign
  • Industry Position: 25% below the Biotechnology median (#691 of 1370)

No single metric tells the full story. See the NIKI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Niki BioSolutions Business Description

Address 17 Hanover Square, London, GBR, W1S 1BN
Aptorum Group Ltd is a clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Aptorum's project pipeline includes SACT-1, a repurposed drug for the treatment of neuroblastoma, and ALS-4, a small molecule for the treatment of bacterial infections caused by Staphylococcus aureus, including but not limited to Methicillin-resistant Staphylococcus aureus (MRSA). Substantially all of the company's revenues are derived from within Hong Kong.
56GF Score

Get the complete analysis for NIKI

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.54
Price
$11.69
GF Value